ORIENTAL: An open label, multicenter, phase IIIb study of first-line durvalumab plus platinum-based chemotherapy in Chinese patients with extensive stage small cell lung cancer (ES-SCLC)
机构:[1]Jilin Provincial Cancer Hospital, Changchun, China[2]National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China[3]Henan Provincial People’s Hospital, Zhengzhou, China[4]The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China[5]Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China[6]Wuhan Union Hospital, Wuhan, China华中科技大学同济医学院附属协和医院[7]The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China浙江省肿瘤医院[8]Ruijin Hospital, Shanghai, China[9]Shandong Cancer Hospital and Institute, Jinan, China[10]Tianjin Lung Cancer Center, Tianjin, China[11]Huashan Hospital, Fudan University, Shanghai, China[12]Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China[13]Affiliated Taizhou Hospital of Zhejiang Province of Wenzhou Medical University, Taizhou, China台州恩泽医疗中心(集团)台州医院[14]The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China[15]The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China中山大学附属第一医院[16]Sichuan Cancer Hospital, Chengdu, China四川省肿瘤医院[17]First affiliated Hospital of Xiamen University, Xiamen, China[18]Harbin Medical University Cancer Hospital, Harbin, China[19]Affiliated Hospital of Hebei University, Baoding, China[20]Medical Affairs, AstraZeneca China, Shanghai, China
第一作者机构:[1]Jilin Provincial Cancer Hospital, Changchun, China
推荐引用方式(GB/T 7714):
Cheng Y.,Wang J.,Cang S.,et al.ORIENTAL: An open label, multicenter, phase IIIb study of first-line durvalumab plus platinum-based chemotherapy in Chinese patients with extensive stage small cell lung cancer (ES-SCLC)[J].JOURNAL OF THORACIC ONCOLOGY.2021,16(4):S727-S728.
APA:
Cheng, Y.,Wang, J.,Cang, S.,Cao, L.,Chen, E....&Gao, M..(2021).ORIENTAL: An open label, multicenter, phase IIIb study of first-line durvalumab plus platinum-based chemotherapy in Chinese patients with extensive stage small cell lung cancer (ES-SCLC).JOURNAL OF THORACIC ONCOLOGY,16,(4)
MLA:
Cheng, Y.,et al."ORIENTAL: An open label, multicenter, phase IIIb study of first-line durvalumab plus platinum-based chemotherapy in Chinese patients with extensive stage small cell lung cancer (ES-SCLC)".JOURNAL OF THORACIC ONCOLOGY 16..4(2021):S727-S728